U.S. markets close in 6 hours
  • S&P 500

    3,871.60
    +60.45 (+1.59%)
     
  • Dow 30

    31,460.23
    +527.86 (+1.71%)
     
  • Nasdaq

    13,418.08
    +225.73 (+1.71%)
     
  • Russell 2000

    2,255.90
    +54.85 (+2.49%)
     
  • Crude Oil

    61.69
    +0.19 (+0.31%)
     
  • Gold

    1,731.70
    +2.90 (+0.17%)
     
  • Silver

    26.89
    +0.45 (+1.70%)
     
  • EUR/USD

    1.2044
    -0.0044 (-0.36%)
     
  • 10-Yr Bond

    1.4190
    -0.0410 (-2.81%)
     
  • GBP/USD

    1.3919
    -0.0003 (-0.02%)
     
  • USD/JPY

    106.6200
    +0.1180 (+0.11%)
     
  • BTC-USD

    48,167.66
    +3,557.85 (+7.98%)
     
  • CMC Crypto 200

    966.53
    +38.30 (+4.13%)
     
  • FTSE 100

    6,572.15
    +88.72 (+1.37%)
     
  • Nikkei 225

    29,663.50
    +697.49 (+2.41%)
     

Recap: Exelixis Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Exelixis (NASDAQ:EXEL) rose in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share decreased 46.15% over the past year to $0.14, which beat the estimate of $0.05.

Revenue of $270,052,000 rose by 12.38% from the same period last year, which beat the estimate of $262,140,000.

Looking Ahead

Exelixis hasn't issued any earnings guidance for the time being.

The upcoming fiscal year's revenue expected to be between $1,150,000,000 and $1,250,000,000.

How To Listen To The Conference Call

Date: Feb 10, 2021

View more earnings on EXEL

Time: 05:00 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/xj465twv

Technicals

Company's 52-week high was at $27.80

Company's 52-week low was at $13.67

Price action over last quarter: Up 11.54%

Company Description

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer (as Cometriq) and advanced renal cell carcinoma, or kidney cancer, and hepatocellular carcinoma, or liver cancer (as Cabometyx). Exelixis and partner Roche have also brought Cotellic to market for the treatment of melanoma.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.